Status:

TERMINATED

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Lead Sponsor:

Eli Lilly and Company

Conditions:

Metastatic Breast Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE4

Brief Summary

The reason for this study is to compare the efficacy of abemaciclib, in combination with fulvestrant, to that of physician's choice of chemotherapy in women with hormone receptor-positive (HR+), human...

Eligibility Criteria

Inclusion

  • Participants must be females of post-menopausal status with HR+, HER2- breast cancer that has spread to internal organs
  • Participants must have had at least one endocrine therapy
  • Participants must be willing to use a device to answer daily questions about how they are doing for the duration of their participation in the study
  • If participant has diarrhea from a previous treatment, they should talk to their doctor to ensure they have recovered enough to participate in this study

Exclusion

  • Participants must not have breast cancer that has spread to the brain if untreated and with symptoms
  • Participants must not have had any systemic treatment after their breast cancer has spread unless it is endocrine therapy
  • Participants must not have certain active infections including HIV or hepatitis
  • Participants must not be pregnant or breastfeeding
  • Participants must not have certain types of cancers or certain previous cancer treatments
  • Participants must not have certain serious medical conditions, including heart or lung disease, or have had certain types of tissue or organ transplants

Key Trial Info

Start Date :

August 14 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 11 2020

Estimated Enrollment :

4 Patients enrolled

Trial Details

Trial ID

NCT04031885

Start Date

August 14 2019

End Date

August 11 2020

Last Update

August 24 2021

Active Locations (61)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 16 (61 locations)

1

Scottsdale Healthcare Hospitals

Avondale, Arizona, United States, 85392

2

University of Arizona Cancer Center

Phoenix, Arizona, United States, 85004

3

Yuma Regional Cancer Center

Yuma, Arizona, United States, 85364

4

CARTI Cancer Center

Little Rock, Arkansas, United States, 72205